Vifor Pharma's Phase III study on its hyperphosphatemia treatment in chronic kidney disease patients has been published in Kidney International. Velphoro (PA21) is a chewable, calcium-free, iron-based phosphate binder that was approved by the U.S. Food and Drug Administration to treat hyperphosphatemia in patients on dialysis in November 2013.

Velphoro was developed by the Swiss company Vifor Pharma and transferred to Vifor Fresenius Medical Care Renal Pharma, and is marketed by Fresenius Medical Care North America.

The Phase 3 study showed that Velphoro (PA21), in a dose of 3-4 tablets per day (one tablet per meal), was as effective in lowering and maintaining serum phosphorus in dialysis patients as sevelamer carbonate with 8-9 tablets per day. Patients treated with Velphoro had a comparable tolerability.

Read the study in Kidney International.

 

Related

Keryx submits application for EU approval of hyperphosphatemia treatment in CKD patients

New chewing gum designed to reduce phosphate levels in chronic kidney disease patients